287 related articles for article (PubMed ID: 25752648)
1. Future clinical uses of neurophysiological biomarkers to predict and monitor treatment response for schizophrenia.
Light GA; Swerdlow NR
Ann N Y Acad Sci; 2015 May; 1344(1):105-19. PubMed ID: 25752648
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal associations between mismatch negativity and disability in early schizophrenia- and affective-spectrum disorders.
Kaur M; Lagopoulos J; Lee RS; Ward PB; Naismith SL; Hickie IB; Hermens DF
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Oct; 46():161-9. PubMed ID: 23851120
[TBL] [Abstract][Full Text] [Related]
3. MMN/P3a deficits in first episode psychosis: comparing schizophrenia-spectrum and affective-spectrum subgroups.
Kaur M; Battisti RA; Ward PB; Ahmed A; Hickie IB; Hermens DF
Schizophr Res; 2011 Aug; 130(1-3):203-9. PubMed ID: 21550211
[TBL] [Abstract][Full Text] [Related]
4. Mismatch negativity (MMN) deficiency: a break-through biomarker in predicting psychosis onset.
Näätänen R; Shiga T; Asano S; Yabe H
Int J Psychophysiol; 2015 Mar; 95(3):338-44. PubMed ID: 25562834
[TBL] [Abstract][Full Text] [Related]
5. Mismatch negativity is a stronger indicator of functional outcomes than neurocognition or theory of mind in patients with schizophrenia.
Lee SH; Sung K; Lee KS; Moon E; Kim CG
Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():213-9. PubMed ID: 24161665
[TBL] [Abstract][Full Text] [Related]
6. Impaired MMN/P3a complex in first-episode psychosis: cognitive and psychosocial associations.
Hermens DF; Ward PB; Hodge MA; Kaur M; Naismith SL; Hickie IB
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Aug; 34(6):822-9. PubMed ID: 20302901
[TBL] [Abstract][Full Text] [Related]
7. Nicotine and the hallucinating brain: effects on mismatch negativity (MMN) in schizophrenia.
Fisher DJ; Grant B; Smith DM; Borracci G; Labelle A; Knott VJ
Psychiatry Res; 2012 Apr; 196(2-3):181-7. PubMed ID: 22425471
[TBL] [Abstract][Full Text] [Related]
8. Translational psychiatry--light at the end of the tunnel.
Jones KA; Menniti FS; Sivarao DV
Ann N Y Acad Sci; 2015 May; 1344():1-11. PubMed ID: 25752480
[TBL] [Abstract][Full Text] [Related]
9. Impaired mismatch negativity generation in prodromal subjects and patients with schizophrenia.
Brockhaus-Dumke A; Tendolkar I; Pukrop R; Schultze-Lutter F; Klosterkötter J; Ruhrmann S
Schizophr Res; 2005 Mar; 73(2-3):297-310. PubMed ID: 15653275
[TBL] [Abstract][Full Text] [Related]
10. Mismatch negativity deficits are associated with poor functioning in schizophrenia patients.
Light GA; Braff DL
Arch Gen Psychiatry; 2005 Feb; 62(2):127-36. PubMed ID: 15699289
[TBL] [Abstract][Full Text] [Related]
11. Alterations of mismatch negativity (MMN) in schizophrenia patients with auditory hallucinations experiencing acute exacerbation of illness.
Fisher DJ; Labelle A; Knott VJ
Schizophr Res; 2012 Aug; 139(1-3):237-45. PubMed ID: 22727705
[TBL] [Abstract][Full Text] [Related]
12. Implication of Electrophysiological Biomarkers in Psychosis: Focusing on Diagnosis and Treatment Response.
Lee HS; Kim JS
J Pers Med; 2022 Jan; 12(1):. PubMed ID: 35055346
[TBL] [Abstract][Full Text] [Related]
13. Contributions of early cortical processing and reading ability to functional status in individuals at clinical high risk for psychosis.
Carrión RE; Cornblatt BA; McLaughlin D; Chang J; Auther AM; Olsen RH; Javitt DC
Schizophr Res; 2015 May; 164(1-3):1-7. PubMed ID: 25728833
[TBL] [Abstract][Full Text] [Related]
14. The right profile: mismatch negativity in schizophrenia with and without auditory hallucinations as measured by a multi-feature paradigm.
Fisher DJ; Labelle A; Knott VJ
Clin Neurophysiol; 2008 Apr; 119(4):909-21. PubMed ID: 18261954
[TBL] [Abstract][Full Text] [Related]
15. Auditory mismatch negativity and P3a in response to duration and frequency changes in the early stages of psychosis.
Nagai T; Tada M; Kirihara K; Yahata N; Hashimoto R; Araki T; Kasai K
Schizophr Res; 2013 Nov; 150(2-3):547-54. PubMed ID: 24012461
[TBL] [Abstract][Full Text] [Related]
16. Mismatch negativity as EEG biomarker supporting CNS drug development: a transnosographic and translational study.
Loiodice S; Drinkenburg WH; Ahnaou A; McCarthy A; Viardot G; Cayre E; Rion B; Bertaina-Anglade V; Mano M; L'Hostis P; Drieu La Rochelle C; Kas MJ; Danjou P
Transl Psychiatry; 2021 Apr; 11(1):253. PubMed ID: 33927180
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic signposts: using biomarkers to guide better treatment of schizophrenia and other psychotic disorders.
Banati R; Hickie IB
Med J Aust; 2009 Feb; 190(S4):S26-32. PubMed ID: 19220170
[TBL] [Abstract][Full Text] [Related]
18. [Recent topics in neurophysiological studies of patients with schizophrenia].
Onitsuka T
Seishin Shinkeigaku Zasshi; 2013; 115(8):847-52. PubMed ID: 24167965
[TBL] [Abstract][Full Text] [Related]
19. Neurophysiological models for new treatment development in schizophrenia: early sensory approaches.
Javitt DC
Ann N Y Acad Sci; 2015 May; 1344():92-104. PubMed ID: 25721890
[TBL] [Abstract][Full Text] [Related]
20. Elementary sensory deficits in schizophrenia indexed by impaired visual mismatch negativity.
Farkas K; Stefanics G; Marosi C; Csukly G
Schizophr Res; 2015 Aug; 166(1-3):164-70. PubMed ID: 26072712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
